串珠镰刀菌（F. moniliforme）和萨氏镰刀菌临床分离株的体外抗真菌药敏性及分子特征分析
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
作者信息
Azor Mónica, Gené Josepa, Cano Josep, Sutton Deanna A, Fothergill Annette W, Rinaldi Michael G, Guarro Josep
机构信息
Unitat de Microbiologia, Facultat de Medicina i Ciències de Salut, Universitat Rovira i Virgili, Reus, Tarragona, Spain.
出版信息
Antimicrob Agents Chemother. 2008 Jun;52(6):2228-31. doi: 10.1128/AAC.00176-08. Epub 2008 Apr 7.
Abstract
A microdilution method was used to test 11 antifungal drugs against clinical isolates of Fusarium thapsinum and three different phylogenetic clades of Fusarium verticillioides that were characterized by sequencing a region of the beta-tubulin gene. Terbinafine was the most-active drug against both species, followed by posaconazole against F. verticillioides.
摘要
采用微量稀释法检测了11种抗真菌药物对尖镰孢菌临床分离株以及轮枝镰孢菌三个不同系统发育分支的活性，这些分支通过对β-微管蛋白基因的一个区域进行测序来表征。特比萘芬是对这两种菌活性最强的药物，其次是泊沙康唑对轮枝镰孢菌的活性。
相似文献
1
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
Antimicrob Agents Chemother. 2008 Jun;52(6):2228-31. doi: 10.1128/AAC.00176-08. Epub 2008 Apr 7.
2
Less-frequent Fusarium species of clinical interest: correlation between morphological and molecular identification and antifungal susceptibility.
J Clin Microbiol. 2009 May;47(5):1463-8. doi: 10.1128/JCM.02467-08. Epub 2009 Mar 25.
3
Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy.
Antimicrob Agents Chemother. 2008 Jul;52(7):2683-5. doi: 10.1128/AAC.00272-08. Epub 2008 Apr 28.
4
Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods.
J Antimicrob Chemother. 2008 Apr;61(4):805-9. doi: 10.1093/jac/dkn022. Epub 2008 Feb 8.
5
Phylogenetic Diversity and In Vitro Susceptibility Profiles of Human Pathogenic Members of the Fusarium fujikuroi Species Complex Isolated from South India.
Mycopathologia. 2018 Jun;183(3):529-540. doi: 10.1007/s11046-018-0248-7. Epub 2018 Feb 14.
6
High genetic diversity and poor in vitro response to antifungals of clinical strains of Fusarium oxysporum.
J Antimicrob Chemother. 2009 Jun;63(6):1152-5. doi: 10.1093/jac/dkp095. Epub 2009 Mar 24.
7
Fusarium keratitis in South India: causative agents, their antifungal susceptibilities and a rapid identification method for the Fusarium solani species complex.
Mycoses. 2013 Sep;56(5):501-11. doi: 10.1111/myc.12062. Epub 2013 Feb 26.
8
Susceptibility of clinical isolates of Fusarium to antifungal drugs.
Mycoses. 1996 Jan-Feb;39(1-2):37-40. doi: 10.1111/j.1439-0507.1996.tb00081.x.
9
In vitro interactions of licensed and novel antifungal drugs against Fusarium spp.
Diagn Microbiol Infect Dis. 2004 Jan;48(1):69-71. doi: 10.1016/j.diagmicrobio.2003.09.003.
10
Keratitis by Fusarium temperatum, a novel opportunist.
BMC Infect Dis. 2014 Nov 12;14:588. doi: 10.1186/s12879-014-0588-y.
引用本文的文献
1
Genomic Insights into Diversity: The Genome of Two Clinical Isolates and Their Demethylase Inhibitor Fungicides Susceptibility.
Pathogens. 2024 Dec 3;13(12):1062. doi: 10.3390/pathogens13121062.
2
An updated list of eumycetoma causative agents and their differences in grain formation and treatment response.
Clin Microbiol Rev. 2024 Jun 13;37(2):e0003423. doi: 10.1128/cmr.00034-23. Epub 2024 May 1.
3
from Diseased Bananas and Human Patients: Susceptibility to Fungicides Used in Clinical and Agricultural Settings.
J Fungi (Basel). 2021 Sep 21;7(9):784. doi: 10.3390/jof7090784.
4
Case Report: Successful Management of Refractory Keratomycosis in an Alpaca Using Penetrating Keratoplasty and Combination Antifungal Therapy (Caspofungin 0.5% and Terbinafine 1%).
Front Vet Sci. 2021 Mar 11;8:644074. doi: 10.3389/fvets.2021.644074. eCollection 2021.
5
Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species.
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.00009-18. Print 2018 May.
6
Antifungal Susceptibility Testing of Fusarium: A Practical Approach.
J Fungi (Basel). 2017 Apr 26;3(2):19. doi: 10.3390/jof3020019.
7
Comparative Evaluation of Etest, EUCAST, and CLSI Methods for Amphotericin B, Voriconazole, and Posaconazole against Clinically Relevant Fusarium Species.
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.01671-16. Print 2017 Jan.
8
Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year Experience.
Open Forum Infect Dis. 2015 Jul 4;2(3):ofv099. doi: 10.1093/ofid/ofv099. eCollection 2015 Sep.
9
Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of molds of the Fusarium genus.
J Clin Microbiol. 2015 Feb;53(2):465-76. doi: 10.1128/JCM.02213-14. Epub 2014 Nov 19.
10
Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment.
Eur J Clin Microbiol Infect Dis. 2013 Dec;32(12):1491-500. doi: 10.1007/s10096-013-1924-7. Epub 2013 Aug 11.
本文引用的文献
1
Cryptic species in Stachybotrys chartarum.
Mycologia. 2002 Sep-Oct;94(5):814-22.
2
Fusarium infections in immunocompromised patients.
Clin Microbiol Rev. 2007 Oct;20(4):695-704. doi: 10.1128/CMR.00014-07.
3
Phylogenetic diversity and microsphere array-based genotyping of human pathogenic Fusaria, including isolates from the multistate contact lens-associated U.S. keratitis outbreaks of 2005 and 2006.
J Clin Microbiol. 2007 Jul;45(7):2235-48. doi: 10.1128/JCM.00533-07. Epub 2007 May 16.
4
Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex.
Antimicrob Agents Chemother. 2007 Apr;51(4):1500-3. doi: 10.1128/AAC.01618-06. Epub 2007 Jan 12.
5
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions.
Clin Infect Dis. 2006 May 15;42(10):1398-403. doi: 10.1086/503425. Epub 2006 Apr 11.
6
Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species.
J Clin Microbiol. 2005 Oct;43(10):4930-42. doi: 10.1128/JCM.43.10.4930-4942.2005.
7
Micafungin: pharmacology, experimental therapeutics and clinical applications.
Expert Opin Investig Drugs. 2005 Apr;14(4):489-509. doi: 10.1517/13543784.14.4.489.
8
[Case report: a Fusarium fungaemia].
Mikrobiyol Bul. 2004 Jul;38(3):265-71.
9
In vitro interactions of licensed and novel antifungal drugs against Fusarium spp.
Diagn Microbiol Infect Dis. 2004 Jan;48(1):69-71. doi: 10.1016/j.diagmicrobio.2003.09.003.
10
Human fusariosis.
Clin Microbiol Infect. 2004 Mar;10 Suppl 1:67-75. doi: 10.1111/j.1470-9465.2004.00845.x.
Zotero 插件